B-Cell therapy Shared Medical Appointments (BCSMA) lead to faster time to treatment and less indirect care

被引：0
|
作者：
Chizmadia, Desiree [1 ]
Rose, Deja [1 ]
Stack, Jennifer [1 ]
Liriano, Amber [1 ]
Glaser, Jessica [1 ]
Rensel, Mary [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
来源：
NEUROLOGY | 2022年 / 98卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P16-7.004
引用
收藏
页数：2
相关论文
共 16 条
  • [1] COMPATIBILITY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY STUDIES IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) FOR INDIRECT TREATMENT COMPARISON (ITC) ANALYSES
    Bonner, A.
    Zhang, Y.
    Hachborn, G.
    Liu, F. F.
    Patel, L.
    Li, D.
    McCoy, C.
    Hasskarl, J.
    Kostic, A.
    VALUE IN HEALTH, 2020, 23 : S28 - S28
  • [2] Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?
    Perez-Lamas, Lucia
    Sandoval-Sus, Jose
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (02) : 139 - 148
  • [3] PHYSICIAN PREFERENCES FOR CAR T THERAPY: TRADING OFF BENEFITS, RISKS, AND TIME TO INFUSION IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Sutphin, J.
    Boeri, M.
    Hauber, B.
    Purdum, A. G.
    VALUE IN HEALTH, 2020, 23 : S19 - S19
  • [4] Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis
    Patel, Vivek
    Baker, Katherine
    Fishman, Danielle
    Lessans, Spencer
    Morris, Trent
    Dholaria, Bhagirathbhai
    Jayani, Reena
    Kassim, Adetola A.
    Kim, Tae Kon
    Morgan, David
    Oluwole, Olalekan O.
    Savani, Bipin N.
    Sengsayadeth, Salyka M.
    Bhaskar, Shakthi
    BLOOD, 2023, 142
  • [5] Skin directed therapy superior to systemic treatment in primary cutaneous B-cell lymphoma? A study from the Charite cutaneous lymphoma registry on time to next treatment
    Cankaya, R.
    Schulz, S.
    Moritz, R.
    Walter, F.
    Schlaak, M.
    Eigentler, T.
    Dobos, G.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S51 - S51
  • [6] LONCASTUXIMAB TESIRINE VERSUS GLOFITAMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Wilson, K.
    Chiodi, F.
    Paine, A.
    Hakimi, Z.
    Mappa, S.
    Crowe, V
    Macmillan, T.
    Eriksson, D.
    Lenz, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [7] Treatment outcome of patients with diffuse large B-cell lymphoma (DLBCL) in routine care who received standard chemoimmunotherapy with MabThera® compared to patients treated with a rituximab biosimilar in first line therapy
    Weide, R.
    Burkhard, O.
    Steinmetz, T.
    Schnell, R.
    Vehling-Kaiser, U.
    Koenigsmann, M.
    Ehscheidt, P.
    Mueller, L.
    Otremba, B.
    Wierecky, J.
    Tamm, I
    Hensel, M.
    Knoblich, J.
    Feiten, S.
    Chakupurakal, G.
    Friesenhahn, V
    Kleboth, K.
    Koepper, H.
    Lutschkin, J.
    Lutz, C.
    Thomalla, J.
    van Roye, C.
    Heymanns, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 65 - 66
  • [8] Treatment of Catheter-Associated Internal Jugular Vein Thrombosis Using Apixaban for Less Than Three Months in Two Patients With Aggressive B-cell Lymphoma Undergoing Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy
    Matsunaga, Takuya
    Kita, Hiroyuki
    Naito, Kazuyuki
    Morimoto, Masako
    Nakanishi, Katsuya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [9] A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
    Park, Jae H.
    Jain, Nitin
    Chen, Andy
    McGuirk, Joseph P.
    Diaz, Monica
    Valamehr, Bahram
    Chu, Yu-Waye
    Castro, Januario E.
    BLOOD, 2020, 136
  • [10] The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
    Christopher Hillis
    Colin Vicente
    Graeme Ball
    PharmacoEconomics, 2022, 40 : 917 - 928
12